{
    "clinical_study": {
        "@rank": "115988", 
        "arm_group": [
            {
                "arm_group_label": "LY2605541", 
                "arm_group_type": "Experimental", 
                "description": "LY2605541 administered subcutaneously (SC) once daily for 26 weeks."
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "arm_group_type": "Active Comparator", 
                "description": "Insulin Glargine administered SC once daily for 26 weeks."
            }
        ], 
        "brief_summary": {
            "textblock": "The purpose of this study is to compare LY2605541 to insulin glargine in Asian insulin na\u00efve\n      participants who have been treated with oral anti hyperglycemia medications.  Participants\n      will receive 26 weeks of treatment."
        }, 
        "brief_title": "A Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment", 
        "completion_date": {
            "#text": "April 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Type 2 Diabetes Mellitus", 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Have Type 2 Diabetes Mellitus (T2DM) for at least 1 year not treated with insulin\n\n          -  Have been receiving at least two oral antihyperglycemic medications (OAMs) for at\n             least 3 months prior to screening\n\n          -  Have Hemoglobin A1c (HbA1c) of 7.0% to 11.0%, inclusive, according to central\n             laboratory at screening\n\n          -  Body mass index (BMI) \u226435.0 kilogram per square meter (kg/m^2)\n\n          -  Inject insulin with a pre-filled insulin pen and perform Self-Monitored Blood Glucose\n             (SMBG)\n\n          -  Record keeping as required by this protocol\n\n          -  Women of childbearing potential are not breastfeeding, have a negative pregnancy test\n             at screening, do not plan to become pregnant during the study, have practiced\n             reliable birth control during the study and 2 weeks following the last dose of\n             investigational product\n\n        Exclusion Criteria:\n\n          -  Have used insulin therapy (outside of pregnancy) anytime in the past 2 years, except\n             for short term treatment of acute conditions\n\n          -  Have been treated with rosiglitazone, pramlintide, glucagon-like peptide-1 (GLP-1)\n             receptor agonist within 3 months prior to screening\n\n          -  Are using or have used any of the following lipid-lowering medications: niacin\n             preparations as a lipid-lowering medication and/or bile acid sequestrants within 90\n             days prior to screening\n\n          -  Local OAM restrictions: have any restrictions for cardiac, renal, and hepatic\n             diseases in the local product regulations\n\n          -  Are taking, or have taken within 3 months before screening, prescription or\n             over-the-counter medications to promote weight loss\n\n          -  Have had any episodes of severe hypoglycemia, diabetic ketoacidosis, or hyperosmolar\n             state/coma within 6 months prior to screening\n\n          -  Have had 1 or more episodes of ketoacidosis or hyperosmolar state/coma in the past 6\n             months\n\n          -  Have cardiac disease with functional status that is New York Heart Association Class\n             III or IV\n\n          -  Have a history of renal transplantation, or are currently receiving renal dialysis or\n             have serum creatinine \u22652.0 milligram per deciliter (mg/dL) (177 micromole per liter\n             [\u03bcmol/L]). Participants taking metformin should not exceed the creatinine level\n             specified in the local label\n\n          -  Have obvious clinical signs or symptoms of liver disease (excluding non-alcoholic\n             fatty liver disease [NAFLD]), acute or any chronic hepatitis, non alcoholic\n             steatohepatitis (NASH), or elevated liver enzyme measurements\n\n          -  Have had a blood transfusion or severe blood loss within 3 months prior to screening\n             or have known hemoglobinopathy, hemolytic anemia or sickle cell anemia, or any other\n             traits of hemoglobin abnormalities known to interfere with the measurement of HbA1c\n\n          -  Have active or untreated cancer, have been in remission from clinically significant\n             cancer(other than basal cell or squamous cell skin cancer) for less than 5 years, or\n             are at increased risk for developing cancer or a recurrence of cancer in the opinion\n             of the investigator\n\n          -  Have known hypersensitivity or allergy to any of LY2605541 and insulin glargine or\n             their excipients\n\n          -  Have pre proliferative and proliferative retinopathy, maculopathy requiring treatment\n             or not clinically stable in the last 6 months, or participants with active changes in\n             subjective eye symptoms as determined by the investigator if an eye exam has not been\n             performed in the last 6 months\n\n          -  Are receiving chronic (lasting longer than 14 consecutive days) systemic\n             glucocorticoid therapy (excluding topical, intranasal, intraocular, and inhaled\n             preparations) or have received such therapy within the 8 weeks immediately preceding\n             screening\n\n          -  Have fasting triglycerides greater than 400 mg/dL (4.5 mmol/L) at screening as\n             determined by the central laboratory\n\n          -  Have an irregular sleep/wake cycle (for example, participants who sleep during the\n             day and work during the night) in the investigator's opinion"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "20 Years"
        }, 
        "enrollment": {
            "#text": "380", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "July 3, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01894568", 
            "org_study_id": "13422", 
            "secondary_id": "I2R-JE-BIAQ"
        }, 
        "intervention": [
            {
                "arm_group_label": "LY2605541", 
                "description": "Administered SC using a prefilled pen.", 
                "intervention_name": "LY2605541", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin Glargine", 
                "description": "Administered SC using a prefilled pen", 
                "intervention_name": "Insulin Glargine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 16, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Aichi", 
                        "country": "Japan", 
                        "zip": "455-8530"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Chiba", 
                        "country": "Japan", 
                        "zip": "277-0825"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Fukuoka", 
                        "country": "Japan", 
                        "zip": "807-0857"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hokkaido", 
                        "country": "Japan", 
                        "zip": "060-0062"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hyogo", 
                        "country": "Japan", 
                        "zip": "662-0971"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ibaraki", 
                        "country": "Japan", 
                        "zip": "311-0113"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kagawa", 
                        "country": "Japan", 
                        "zip": "765-0071"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kanagawa", 
                        "country": "Japan", 
                        "zip": "247-0056"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kumamoto", 
                        "country": "Japan", 
                        "zip": "862-0976"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Kyoto", 
                        "country": "Japan", 
                        "zip": "6150035"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miyagi", 
                        "country": "Japan", 
                        "zip": "980-0021"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miyazaki", 
                        "country": "Japan", 
                        "zip": "880-0034"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Nagano", 
                        "country": "Japan", 
                        "zip": "399-0006"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Ooita", 
                        "country": "Japan", 
                        "zip": "8700039"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Osaka", 
                        "country": "Japan", 
                        "zip": "569-1096"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tochigi", 
                        "country": "Japan", 
                        "zip": "323-0022"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Tokyo", 
                        "country": "Japan", 
                        "zip": "143-8541"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Yamaguchi", 
                        "country": "Japan", 
                        "zip": "754-0002"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Active, not recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Daegu", 
                        "country": "Korea, Republic of", 
                        "zip": "700-712"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Incheon", 
                        "country": "Korea, Republic of", 
                        "zip": "405-760"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Pusan", 
                        "country": "Korea, Republic of", 
                        "zip": "602-739"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Seoul", 
                        "country": "Korea, Republic of", 
                        "zip": "158-710"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Ulsan-Si", 
                        "country": "Korea, Republic of", 
                        "zip": "682-714"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Wonju-Si", 
                        "country": "Korea, Republic of", 
                        "zip": "220-701"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Jhonghe City", 
                        "country": "Taiwan", 
                        "zip": "235"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Sindian City", 
                        "country": "Taiwan", 
                        "zip": "23148"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Taichung", 
                        "country": "Taiwan", 
                        "zip": "404"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Taichung County", 
                        "country": "Taiwan", 
                        "zip": "433"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Tainan", 
                        "country": "Taiwan", 
                        "zip": "70403"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Taipei", 
                        "country": "Taiwan", 
                        "zip": "220"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }, 
            {
                "contact": {
                    "last_name": "Eli Lilly"
                }, 
                "facility": {
                    "address": {
                        "city": "Yong Kung City", 
                        "country": "Taiwan", 
                        "zip": "71004"
                    }, 
                    "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": [
                "Japan", 
                "Korea, Republic of", 
                "Taiwan"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase 3, Open Label, Randomized, Parallel, 26 Week Treatment Study Comparing LY2605541 With Insulin Glargine as Basal Insulin Treatment in Combination With Oral Anti Hyperglycemia Medications in Asian Insulin Na\u00efve Patients With Type 2 Diabetes Mellitus", 
        "overall_contact": {
            "last_name": "There may be multiple sites in this clinical trial. 1-877-CTLILLY (1-877-285-4559) or", 
            "phone": "1-317-615-4559"
        }, 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": [
                "Japan: Pharmaceuticals and Medical Devices Agency", 
                "Taiwan : Food and Drug Administration", 
                "South Korea: Korea Food and Drug Administration (KFDA)"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "January 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "Change from Baseline to 26 Weeks in Hemoglobin A1c (HbA1c)", 
            "safety_issue": "No", 
            "time_frame": "Baseline, 26 Weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01894568"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "30-Day Adjusted Rate of Total and Nocturnal Hypoglycemic Events", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 26 Weeks"
            }, 
            {
                "measure": "Fasting Serum Glucose (FSG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to Weeks 4, 8, 12, 16 and 26"
            }, 
            {
                "measure": "Fasting Blood Glucose (FBG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 26 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 26 Weeks in Body Weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 26 Weeks"
            }, 
            {
                "measure": "9-Point Self-Monitored Blood Glucose (SMBG)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 26 Weeks"
            }, 
            {
                "measure": "Proportion of Participants with HbA1c \u22646.5%", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 26 Weeks"
            }, 
            {
                "measure": "Insulin Dose per Kilogram (kg) of Body Weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 26 Weeks"
            }, 
            {
                "measure": "Time to Steady State for Basal Insulin (Stable Maximum Dose)", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 26 Weeks"
            }, 
            {
                "measure": "Triglycerides, Total Cholesterol, Low-Density Lipoprotein (LDL-C), and High-Density Lipoprotein Cholesterol (HDL-C)", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline to 26 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 26 Weeks in Anti-LY2605541 Antibodies", 
                "safety_issue": "Yes", 
                "time_frame": "Baseline, 26 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 26 Weeks in EuroQoL-5 Dimension (EQ-5D) Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 26 Weeks"
            }, 
            {
                "measure": "Insulin Treatment Satisfaction Questionnaire (ITSQ) Score", 
                "safety_issue": "No", 
                "time_frame": "Week 4 and 26"
            }, 
            {
                "measure": "Change from Baseline to 26 Weeks in Adult Low Blood Sugar Survey (LBSS) Scores", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 26 Weeks"
            }, 
            {
                "measure": "Intra-Participant Variability of the Fasting Blood Glucose (FBG)", 
                "safety_issue": "No", 
                "time_frame": "26 Weeks"
            }, 
            {
                "measure": "Change from Baseline to 12 Weeks in Hemoglobin A1c (HbA1c)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 12 Weeks"
            }, 
            {
                "measure": "Hemoglobin A1c", 
                "safety_issue": "No", 
                "time_frame": "26 Weeks"
            }, 
            {
                "measure": "Percentage of Participants with Total and Nocturnal Hypoglycemic Events", 
                "safety_issue": "No", 
                "time_frame": "Baseline to 26 Weeks"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}